<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01948908</url>
  </required_header>
  <id_info>
    <org_study_id>AAAL7510</org_study_id>
    <nct_id>NCT01948908</nct_id>
  </id_info>
  <brief_title>Volumes of Administration for Intranasal Midazolam</brief_title>
  <official_title>Optimal Volumes of Administration for Intranasal Midazolam in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine exactly how much drug volume should be administered
      into each nare, so that the drug absorption can be maximized and the amount that runs out of
      the nose, or is swallowed, is minimized, thereby optimizing the effectiveness of any drug
      given intranasally. The investigators will determine this ideal &quot;volume of administration&quot; by
      studying intranasal midazolam in children who require sedation to facilitate laceration
      repairs. The investigators will evaluate both clinical outcomes as well as pharmacokinetic
      outcomes associated with each volume of administration. We will block randomize children to
      receive intranasal midazolam in maximum aliquots of one of the three following VOA: 200
      microliters (mcL), 500 mcL, or 1000 mcL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intranasal route is an effective means of administering sedative medications for
      children. However, sometimes the child has to receive a certain dose that requires a very
      large volume to be administered into the nose, because of the types of concentrations of
      drugs that are available. Most drugs are not concentrated enough so that small volumes can be
      consistently given, so as a result, sometimes a very large amount of medication is
      administered intranasally. When the amount is too large, most of the medication either runs
      back out the nose, or down the back of the nose and throat and is swallowed, instead of being
      absorbed in the nasal cavity, where it can be quickly absorbed and produce optimal
      effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time (Minutes) After Administration of Intranasal Midazolam Until Patient Achieves Minimal Sedation</measure>
    <time_frame>20 minutes</time_frame>
    <description>This outcome is designed to examine time to onset of minimal sedation, defined as a University of Michigan Sedation Score (UMSS) of 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observational Scale of Behavioral Distress - Revised</measure>
    <time_frame>60 minutes</time_frame>
    <description>The Observational Scale of Behavioral Distress - revised (OSBD-r) is an eight-factor, weighted observational scale used to measure distress associated with medical procedures in children 1 to 20 years of age. The total OSBD-r score is the sum of the OSBD-r scores for predetermined clinically relevant phases of the procedure, with each phase assigned a score from 0 to 23.5 (0=no distress, 23.5=maximum distress), based on the frequency and types of behaviors observed during a pre-determined number of 15-second intervals during each phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Physicians Who Were Satisfied or Very Satisfied With Ease of Medication Administration</measure>
    <time_frame>60 minutes</time_frame>
    <description>This outcome is designed to examine MD satisfaction with ease of administration of intranasal medication - physicians who expressed that they were satisfied or very satisfied with ease of medication administration will be counted.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Children Requiring Sedation to Facilitate Laceration Repair</condition>
  <arm_group>
    <arm_group_label>200 mcL VOA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal midazolam administered in 200 mcL VOA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mcL VOA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal midazolam administered in 500 mcL VOA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mcL VOA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal midazolam administered in 1000 mcL VOA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal midazolam</intervention_name>
    <description>Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
    <arm_group_label>200 mcL VOA</arm_group_label>
    <arm_group_label>500 mcL VOA</arm_group_label>
    <arm_group_label>1000 mcL VOA</arm_group_label>
    <other_name>No other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 to 7 years of age, inclusive.

          -  Require intranasal midazolam for minimal sedation to facilitate laceration repair.

        Exclusion Criteria:

          -  Weight less than 10 kg.

          -  Known allergy to midazolam.

          -  Presence of intranasal obstruction (e.g. mucous or blood) that cannot be readily
             cleared

          -  Inability to speak English or Spanish

          -  Developmental delay, psychiatric illness, neurologic impairment, or altered mental
             status; or illnesses associated with chronic pain (e.g. sickle cell disease,
             inï¬‚ammatory bowel disease).

          -  Foster children or wards.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2013</study_first_posted>
  <results_first_submitted>March 5, 2016</results_first_submitted>
  <results_first_submitted_qc>April 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2016</results_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Daniel Sing-Kwong Tsze</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Laceration repair</keyword>
  <keyword>Children</keyword>
  <keyword>Intranasal</keyword>
  <keyword>Midazolam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>200 mcL VOA</title>
          <description>Intranasal midazolam administered in 200 mcL VOA
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
        <group group_id="P2">
          <title>500 mcL VOA</title>
          <description>Intranasal midazolam administered in 500 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
        <group group_id="P3">
          <title>1000 mcL VOA</title>
          <description>Intranasal midazolam administered in 1000 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>200 mcL VOA</title>
          <description>Intranasal midazolam administered in 200 mcL VOA
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
        <group group_id="B2">
          <title>500 mcL VOA</title>
          <description>Intranasal midazolam administered in 500 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
        <group group_id="B3">
          <title>1000 mcL VOA</title>
          <description>Intranasal midazolam administered in 1000 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="2.4" upper_limit="5.6"/>
                    <measurement group_id="B2" value="2.7" lower_limit="2.1" upper_limit="3.5"/>
                    <measurement group_id="B3" value="2.7" lower_limit="1.9" upper_limit="3.9"/>
                    <measurement group_id="B4" value="2.9" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic, White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic, Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic, Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time (Minutes) After Administration of Intranasal Midazolam Until Patient Achieves Minimal Sedation</title>
        <description>This outcome is designed to examine time to onset of minimal sedation, defined as a University of Michigan Sedation Score (UMSS) of 1.</description>
        <time_frame>20 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mcL VOA</title>
            <description>Intranasal midazolam administered in 200 mcL VOA
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
          <group group_id="O2">
            <title>500 mcL VOA</title>
            <description>Intranasal midazolam administered in 500 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
          <group group_id="O3">
            <title>1000 mcL VOA</title>
            <description>Intranasal midazolam administered in 1000 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time (Minutes) After Administration of Intranasal Midazolam Until Patient Achieves Minimal Sedation</title>
          <description>This outcome is designed to examine time to onset of minimal sedation, defined as a University of Michigan Sedation Score (UMSS) of 1.</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="3.8" upper_limit="5.4"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.9" upper_limit="4.9"/>
                    <measurement group_id="O3" value="5.2" lower_limit="4.6" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observational Scale of Behavioral Distress - Revised</title>
        <description>The Observational Scale of Behavioral Distress - revised (OSBD-r) is an eight-factor, weighted observational scale used to measure distress associated with medical procedures in children 1 to 20 years of age. The total OSBD-r score is the sum of the OSBD-r scores for predetermined clinically relevant phases of the procedure, with each phase assigned a score from 0 to 23.5 (0=no distress, 23.5=maximum distress), based on the frequency and types of behaviors observed during a pre-determined number of 15-second intervals during each phase.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mcL VOA</title>
            <description>Intranasal midazolam administered in 200 mcL VOA
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
          <group group_id="O2">
            <title>500 mcL VOA</title>
            <description>Intranasal midazolam administered in 500 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
          <group group_id="O3">
            <title>1000 mcL VOA</title>
            <description>Intranasal midazolam administered in 1000 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
        </group_list>
        <measure>
          <title>Observational Scale of Behavioral Distress - Revised</title>
          <description>The Observational Scale of Behavioral Distress - revised (OSBD-r) is an eight-factor, weighted observational scale used to measure distress associated with medical procedures in children 1 to 20 years of age. The total OSBD-r score is the sum of the OSBD-r scores for predetermined clinically relevant phases of the procedure, with each phase assigned a score from 0 to 23.5 (0=no distress, 23.5=maximum distress), based on the frequency and types of behaviors observed during a pre-determined number of 15-second intervals during each phase.</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" lower_limit="3.68" upper_limit="8.44"/>
                    <measurement group_id="O2" value="7.90" lower_limit="4.95" upper_limit="10.85"/>
                    <measurement group_id="O3" value="8.56" lower_limit="5.75" upper_limit="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Physicians Who Were Satisfied or Very Satisfied With Ease of Medication Administration</title>
        <description>This outcome is designed to examine MD satisfaction with ease of administration of intranasal medication - physicians who expressed that they were satisfied or very satisfied with ease of medication administration will be counted.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 mcL VOA</title>
            <description>Intranasal midazolam administered in 200 mcL VOA
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
          <group group_id="O2">
            <title>500 mcL VOA</title>
            <description>Intranasal midazolam administered in 500 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
          <group group_id="O3">
            <title>1000 mcL VOA</title>
            <description>Intranasal midazolam administered in 1000 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Physicians Who Were Satisfied or Very Satisfied With Ease of Medication Administration</title>
          <description>This outcome is designed to examine MD satisfaction with ease of administration of intranasal medication - physicians who expressed that they were satisfied or very satisfied with ease of medication administration will be counted.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of administration of intranasal midazolam until emergency department discharge, an average of 1 hour.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>200 mcL VOA</title>
          <description>Intranasal midazolam administered in 200 mcL VOA
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
        <group group_id="E2">
          <title>500 mcL VOA</title>
          <description>Intranasal midazolam administered in 500 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
        <group group_id="E3">
          <title>1000 mcL VOA</title>
          <description>Intranasal midazolam administered in 1000 mcL VOA.
Intranasal midazolam: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Vomiting after administration of intranasal midazolam</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Inadequate sedation</sub_title>
                <description>Did not achieve sedation adequate for completion of laceration repair</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel S. Tsze</name_or_title>
      <organization>Columbia University College of Physicians and Surgeons</organization>
      <phone>212-305-9825</phone>
      <email>dst2141@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

